Daiichi Sankyo Inc, the US subsidiary of Daiichi Sankyo Company, will merge with its US-based sister company, Asubio Pharmaceuticals. As a result, Asubio Pharmaceuticals projects will be integrated into the Daiichi Sankyo global development organisation, led by Mahmoud Ghazzi.
Asubio Pharmaceuticals’ parent company, Asubio Pharma Co, which is based in Japan, will continue to operate as a wholly owned subsidiary of Daiichi Sankyo Co, with a focus on discovery research.
Asubio Pharmaceuticals’s ongoing clinical trial in patients with acute spinal cord injury (ASBI 603ASCENT study (SUN13837)) has already completed enrolment. An analysis and dissemination of the data will now be managed by Daiichi Sankyo.
“In line with the Daiichi Sankyo five-year business plan to optimise our business of delivering innovative treatments to patients, consolidating the current Asubio US projects under the company’s overall research and development organisation helps us streamline our operations,” said Glenn Gormley, senior executive officer and global head of research and development, Daiichi Sankyo Company, and executive chairman and president, Daiichi Sankyo, Inc.
